ABC’s of Parkinson’s Disease 4/29/15 Karen Parenti, MS, PsyD.

Slides:



Advertisements
Similar presentations
MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
Advertisements

Linda Pituch, Patient Services Manager, Parkinson’s Disease Foundation
Parkinson’s Finding the cure Presentation
The PARticulars of Parkinson’s Disease
Motor Neurone Disease Different types & Life Expectancy
Parkinson’s disease Interventions Whitney Mundy Dr. Davis.
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
“To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” Ralph Waldo Emerson.
By: Emily Millet And Olivia Hitt. Nerve damage is also called neuropathy it is when the nerves of your body die. It may affect the peripheral nerves or.
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Bipolar Disorder Bailey Roy. Definition Bipolar disorder causes extreme shifts in mood, energy, thinking, and behavior–from the highs of mania on one.
Deep Brain Stimulation For parkinson’s disease
Schizoaffective Disorder What is it? How does it affect the person diagnosed? How is it dealt with? What is it? How does it affect the person diagnosed?
Gene Therapy in Huntington’s Disease Project was done by Rejan Chin & Sharisa Ford.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
Parkinson’s Disease Busra Berika Yucel
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Parkinson’s Disease By Devin Cornford
Parkinson's Disease Katherine Patetta March 6, 2013 Period 1.
Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative.
Huntington Disease Genetic Disorder Project Alaukika Desai AP Biology Period 3.
ALZHEIMER’S PART 2. AD VIDEO
DEMENTIA AND ALZHEIMER'S DISEASE. IMPAIRMENT OF BRAIN FUNCTION ( DECLINE IN INTELLECTUAL FUNCTIONING) THAT INTERFERES WITH ROUTINE DAILY ACTIVITIES. MENTAL.
Health Presentation Amyotrophic Lateral Sclerosis Zhenette Stevens.
Parkinson’s Disease. Definition Parkinson's disease (PD) is an idiopathic, slowly progressive, neurodegenerative disorder whereby two or more of the following.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
PARKINSON’S DISEASE By Courtney and Niral. WHAT IS IT?  Parkinson's disease (PD) is chronic and progressive movement disorder, meaning that symptoms.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
By: Jackie Lillo Period 3 MULTIPLE SCLEROSIS. INHERITANCE  Multiple Sclerosis, or MS, is an autoimmune disease that affects the central nervous system.
 Parkinson Disease (PD) is a disorder of the brain that causes a variety of movement problems.
PARKINSON’S DISEASE By: AARUSHI JAIN AMRUTA KAMBLE ANNETT MARY JACOB AVANTI DEO M.Sc. PRIST (09-11)
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
NERVOUS SYSTEM Sydney Hirrschoff. NERVOUS SYSTEM FUNCTION The nervous system is made up of the brain, spinal cord, sensory organs, and all of the nerves.
Sarah Ehlers & Brendan Valentine Parkinson’s Disease.
Douglas Todey. Functions It has three main basic functions Sensory neurons receive information from sensory receptors Interneurons transfer and interpret.
CASE 1 Olivia Clements, Cade Mersch, and Julia Calhoun.
Neurological Disorders
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease By: Walter Gerring and Seth Little.
By Katelyn Chaimson and Sean Guyot
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
The Substantia Nigra THE BRAIN Symptoms differ from every person suffering from the disease. There are two types of symptoms, primary, secondary.
Parkinson’s Disease Sheila Mulhern. Parkinson’s Disease Stats (PDF)  One million Americans live with Parkinson's disease, - more than the combined number.
 Parkinson Disease (PD) is a progressive disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
Parkinson’s Test Device Development Tiffany Feltman Erin Sikkel.
Pathogenesis and pathology of parkinsonism
Neurotransmitters in the brain By Joon Kim. Neurotransmitters  A neurotransmitter is a specialized messenger chemical that transfers or sends information.
PARKINSON’S ADAM KREAMER. WHAT IS PARKINSON’S? *Parkinson’s disease, also called PD, is categorized as a motor system disorder, which is a result of the.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Do Now 2/9/15 1.Describe possible causes for forgetting a memory. 2.Compare and contrast semantic and episodic memories.
Parkinson’s Disease By: Taylor Hawkins, Ana McGhee, and Morgan Zander.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Team (Phoenix) Presents Parkinson’s Disease Prepared in partial satisfaction of the requirements for GPC 126, Physiological Psychology Spring Semester,
Chris Allred NS 215 ?id= &page=1&CMP=O TC-RSSFeeds0312.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Parkinson’s Disease Jose S. Santiago M.D..
Module 7.3 Movement Disorders
Schizophrenia: an inside view
Alzheimer’s Disease.
Falon Fiorillo & Breeanna Fournier
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Amyotrophic Lateral Sclerosis
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
Long Term Effects of Concussions
Alzheimer's.
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

ABC’s of Parkinson’s Disease 4/29/15 Karen Parenti, MS, PsyD

What is Parkinson’s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, sometimes starting with a barely noticeable tremor in just one hand. But while a tremor may be the most well-known sign of Parkinson's disease, the disorder also commonly causes stiffness or slowing of movement. In the early stages of Parkinson's, the face may show little or no expression or the arms may not swing when walking. Speech may become soft or slurred. These symptoms worsen as the condition progresses over time. Although Parkinson's disease can't be cured, medications may markedly improve symptoms. In occasional cases, surgery is suggested to regulate certain regions of the brain and improve symptoms.

Statistics  As many as one million Americans live with Parkinson's disease, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy and ALS.  Approximately 60,000 Americans are diagnosed with Parkinson's disease each year, and this number does not reflect the thousands of cases that go undetected.  An estimated seven to 10 million people worldwide are living with Parkinson's disease.  Incidence of Parkinson’s increases with age, but an estimated four percent of people with PD are diagnosed before the age of 50.  Men are one and one half times more likely to have Parkinson's than women. 3

Symptoms The diagnosis of PD depends upon the presence of one or more of the four most common motor symptoms of the disease. In addition, there are other secondary and non motor symptoms that affect many people and are increasingly recognized as important to treating Parkinson’s. Each person with Parkinson's will experience symptoms differently. For example, many people experience tremors as their primary symptom, while others may not have tremors, but may have problems with balance. Also, for some people the disease progresses quickly, and in others it does not. Although some people with Parkinson’s only have symptoms on one side of the body for many years, eventually the symptoms begin on the other side. Symptoms on the other side of the body often do not become as severe as symptoms on the initial side. 4

Common Symptoms Main Motor Symptoms of PD according to Mayo clinic: Shaking or tremor at rest. Slowness of movement, called bradykinesia. Stiffness or rigidity of the arms, legs or trunk. Trouble with balance and falls, also called postural instability. Speech changes, writing changes 5

Causes To date, despite decades of intensive study, the causes of Parkinson’s remain unknown. It is believed that the disease is caused by a combination of genetic and environmental factors, which may vary from person to person. In some people, genetic factors may play a role; in others, illness, an environmental toxin or other event may contribute to PD. Scientists have identified aging as an important risk factor; there is a two to four percent risk for Parkinson’s among people over age 60, compared with one to two percent in the general population. The chemical or genetic trigger that starts the cell death process in dopamine neurons is the subject of intense scientific study. Experts believe that by understanding the sequence of events that leads to the loss of dopamine cells, scientists will be able to develop treatments to stop or reverse the disease 6

Causes Genetic Factors – according to CDC The vast majority of Parkinson's cases are not directly inherited. About 15 to 25 percent of people with Parkinson’s report having a relative with the disease. In large population studies, researchers have found that people with an affected first-degree relative, such as a parent or sibling, have a four to nine percent higher chance of developing PD, as compared to the general population. Researchers have discovered several gene mutations that can cause the disease directly, but these affect only a small number of families. Some of these mutations involve genes that play a role in dopamine cell functions. Parkinson’s has developed at an early age in individuals with mutations in genes for parkin, PINK1, LRRK2, DJ-1, and glucocerebrosidase, among others. Genetics is the subject of intense research. 7

Causes Environmental Factors Some scientists have suggested that Parkinson's disease may result from exposure to an environmental toxin or injury. Epidemiological research has identified several factors that may be linked to Parkinson’s, including rural living, well water, manganese and pesticides. Some studies have demonstrated that prolonged occupational exposure to certain chemicals is associated with an elevated risk of PD. These include the insecticides permethrin and beta-hexachlorocyclohexane (beta-HCH), the herbicides paraquat and 2,4-dichlorophenoxyacetic acid and the fungicide maneb. In 2009, the US Department of Veterans Affairs added Parkinson’s to a list of diseases possibly associated with exposure to Agent Orange. A synthetic neurotoxin agent called MPTP can also cause immediate and permanent parkinsonism. The compound was discovered in the 1980s in individuals who injected themselves with a synthetic form of heroin contaminated with MPTP. Cases of MPTP-induced Parkinson’s in the general population are exceedingly rare. 8

Progression The progression of Parkinson’s disease varies among different individuals. Parkinson's is chronic and slowly progressive. Parkinson's is not considered a fatal disease. The way that it progresses is different for everyone. Movement symptoms vary from person to person, and so does the rate at which they progress. Some are more bothersome than others depending on what a person normally does during the day. Some people with Parkinson's live with mild symptoms for many years, whereas others develop movement difficulties more quickly. Non motor symptoms also are very individualized, and they affect most people with Parkinson's at all stages of the disease. Some people with Parkinson's find that symptoms such as depression or fatigue interfere more with daily life than do problems with movement. 9

Severity Mild Parkinson’s  Movement symptoms may be inconvenient, but do not affect daily activities  Movement symptoms, often tremor, occur on one side of the body  Friends may notice changes in a person’s posture, walking ability or facial expression  Parkinson's medications suppress movement symptoms effectively  Regular exercise improves and maintains mobility, flexibility, range of motion and balance, and also reduces depression and constipation 10

Severity Moderate Parkinson’s  Movement symptoms occur on both sides of the body  The body moves more slowly  Trouble with balance and coordination may develop  “Freezing” episodes — when the feet feel stuck to the ground — may occur  Parkinson's medications may “wear off” between doses  Parkinson's medications may cause side effects, including dyskinesias (involuntary movements)  Regular exercise, perhaps with physical therapy, continues to be important for good mobility and balance  Occupational therapy may provide strategies for maintaining independence 11

Severity Advanced Parkinson’s  Great difficulty walking; in wheelchair or bed most of the day  Not able to live alone  Assistance needed with all daily activities  Cognitive problems may be prominent, including hallucinations and delusions  Balancing the benefits of medications with their side effects becomes more challenging 12

Medications and Treatment Although there are general guidelines that doctors use to choose a treatment regimen, the CDC recommends that each person with PD be individually evaluated to determine which drug or combination of drugs is best for them. For some, a “first choice” drug might be one of the levodopa preparations, and for others, an initial prescription may be given for one of the agonists, an MAO inhibitor or an anticholinergic. The choice of drug treatment depends on many variables including symptom presentation, other concurrent health issues (and the medications being used to treat them) and a person’s age. 13

Surgical Treatments Surgery for Parkinson's disease has come a long way since it was first developed more than 50 years ago. The newest version of this surgery, deep brain stimulation (DBS), was developed in the 1990s and is now a standard treatment. Worldwide, about 30,000 people have had deep brain stimulation. What is DBS? During deep brain stimulation surgery, electrodes are inserted into the targeted brain region using MRI and neurophysiological mapping to ensure that they are implanted in the right place. A device called an impulse generator or IPG (similar to a pacemaker) is implanted under the collarbone to provide an electrical impulse to a part of the brain involved in motor function. Those who undergo the surgery are given a controller, which allows them to check the battery and to turn the device on or off. An IPG battery lasts for about three to five years and is relatively easy to replace under local anesthesia. 14

LSVT Treatment for PD LSVT™ therapy uses innovative and clinically-proven methods for improving communication and movement in individuals with Parkinson disease with application to other neural conditions, such as stroke, multiple sclerosis, cerebral palsy, and Down syndrome. The LSVT programs have been developed and scientifically researched over the past 20 years with funding from the National Institutes of Health. Research on LSVT BIG (Physical/Occupational) therapy has documented improved ratings on tests of motor functioning in people with Parkinson’s Disease following treatment, including: faster walking and bigger steps, improved balance and increased trunk rotation. LSVT Loud (speech) therapy is considered the gold standard in treating speech disorders for people with Parkinson’s Disease and has demonstrated improved vocal loudness, improved speech intelligibility, and more facial expression. 15

Background on LSVT In 1986, a woman named Lee Silverman sought treatment for Parkinson’s disease. Her family wished there was a way they could hear and understand her speech. At the request of the Silverman family, researcher Dr. Lorraine Ramig and speech therapist Carolyn Bonitati, developed a voice therapy that helps people with Parkinson’s Disease regain their ability to speak. In honor of Mrs. Silverman and the success of this therapy, the technique was named LSVT™, Lee Silverman Voice Treatment. This technique has also been applied to physical and occupational therapy for persons with Parkinson’s disease. People with Parkinson’s disease have a loss of automaticity as the disease progresses, requiring greater conscious attention to tasks. When required to perform dual tasks or tasks simultaneously, there are insufficient resources which results in a decrease in one or both of the concurrent tasks. LSVT™ treatment focuses on using parallel behavior to retrain the nerves. Therapists focus on “Loud” and “Big” respectively when performing speech and physical/occupational therapy to maximize attention to the task at hand and increasing automaticity. 16

Research on PD Treatments According to the FDA, the medicines in the R&D pipeline in 2014 offer hope of reducing the human and economic costs of Parkinson’s disease. Some of these potential advances include:  A gene therapy that targets the part of the brain that controls movement.  A new medicine that targets a receptor found in the brain where degeneration and abnormality are often seen in Parkinson’s disease.  New delivery mechanisms of approved treatments, including an intranasal formulation and an intestinal gel. 17

Parkinson’s Video Clip 18

Parkinson’s Video Clip ohttps:// o. 19

Questions/Comments 20